Serial Coronary CTA-based Plaque Progression Detection for Management of Coronary Heart Disease

Patients with non-obstructive coronary artery disease have a high rate of adverse cardiovascular events, and currently, there is still a lack of effective management strategies for these patients in clinical practice. In the SUCCESS study, investigator will compare follow-up CCTA management with routine clinical management to assess the effectiveness of follow-up CCTA in improving lipid control and reducing cardiovascular events in these patients.

The SUCCESS study is a multicenter, randomized, parallel-controlled, interventional clinical trial that recruits patients with non-obstructive coronary artery disease identified on previous CCTA (coronary artery stenosis of 20% to 70% or left main coronary artery stenosis of 20% to 50%). The experimental group is the CCTA follow-up management group, and the control group is the routine clinical follow-up management group. All participants will be randomly assigned to the experimental and control groups in a 1:1 ratio. The experimental group will undergo management using follow-up CCTA, while the control group will be managed using routine clinical and laboratory examinations. At the 1-year follow-up, all participants will undergo laboratory re-examination to observe the impact of follow-up CCTA on lipid target achievement. After 3 years of follow-up, the differences in the occurrence of major adverse cardiovascular and cerebrovascular events (MACCE) between the two groups will be compared.

Inclusion criteria

• Age between 18 and 80 years old;
• Known patients with non-obstructive coronary artery disease (disease duration ≥2 years);
• Patients who agree to undergo follow-up CCTA examinations and cooperate in completing follow-up observations.

Exclusion criteria

• Patients who have experienced ACS or PCI/CABG;
• Patients who have experienced adverse cardiovascular and cerebrovascular events;
• Patients who have undergone follow-up CCTA or DSA examinations before enrollment;
• Patients with severe hepatic and renal dysfunction;
• Patients with contraindications to CCTA examinations;
• Patients with poor initial CCTA image quality or data loss.